SCHEMBL4708887

SCHEMBL4708887

CC(=O)c1c(-c2cccc(F)c2)nn(C(C)C)c(=O)c1Nc1cccc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CSNK1E P49674 3/20 0.38
▸ CSNK1D P48730 2/20 0.38
▸ TDO2 P48775 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ PPARG P37231 1/20 0.37
▸ NR2E3 Q9Y5X4 1/20 0.37
▸ NCOR2 Q9Y618 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GPR35 Q9HC97 1/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ KDM1A O60341 1/20 0.36
▸ ALPL P05186 1/20 0.36
▸ ALPI P09923 1/20 0.36
▸ ALPG P10696 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4705814 0.90 PDE4B (0.48) PDE4BSMN1; SMN2MAPTPPARGNR2E3
SCHEMBL4707163 0.88 PDE4B (0.48) PDE4BRAB9ASMN1; SMN2MAPTLMNA
SCHEMBL4706663 0.87 CSNK1E (0.41) PDE4BCSNK1ECSNK1DPARP1BUB1
SCHEMBL4708502 0.87 KCNK3 (0.41) PDE4BCSNK1ECSNK1DTP53BUB1
SCHEMBL3033451 0.86 CSNK1E (0.45) PDE4BCSNK1ECSNK1DLMNA
SCHEMBL4706113 0.85 PDE4B (0.38) PDE4BKMT2AMEN1CSNK1ECSNK1D
SCHEMBL4706986 0.85 PDE4B (0.57) PDE4BKMT2ARAB9AMEN1SMN1; SMN2
SCHEMBL4707884 0.84 PDE4B (0.45) PDE4BKMT2ACSNK1ECSNK1DALPL
SCHEMBL4705819 0.83 PDE4B (0.46) PDE4BKMT2ARAB9AMEN1SMN1; SMN2
SCHEMBL4706564 0.83 RAB9A (0.39) PDE4BKMT2ARAB9AMEN1CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 — — US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 — — US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885KMT2A 2517/4885RAB9A 2162/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885KMT2A 2517/4885RAB9A 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback